The CEO of Novo Nordisk, Lars Jorgesen, testifies before an audience of the Health, Education, Labor and Pensions of the Senate on the prices of the US.
Piroschka Van de Wouw | Reuters
Novo Nordisk On Friday he said that the CEO Lars Fruerdaard Jørgensen renounces as the couples manufacturer seeks to relive his lucky one in the midst of a growing competition.
The Danish pharmaceutical giant said that Jørgensen would remain in his position “for a period to support a transition without problems to a new leadership.” He added that the search for a replacement was turning on and an advertise would be due in due time.
Novo Nordisk’s actions were last negotiated by 3% lower. Meanwhile, the actions of rival Obesity Drug Maker Eli Lilly They had a 1.6% negotiation prior to marketing.
The decision occurs when the price of Novo Nordisk actions has abuse tasks during the past year in the midst of greater competition in the obesity drug market in globe and the disappointing results of the trial for their next general treatments.
The price of the company’s shares has currently dropped by more than 50% since mid -2024.
“Novo Nordisk’s strategy remains unchanged, and the Board trusts the company’s current business plans and its ability to execute the plans,” said President Helge Lund in a statement.
“However, the changes are made in the light of the recent market challenges that Novo Nordisk has been facing and the development of the company’s shares since mid -2014,” the company said in a statement.
In relation to the change, the company said that the president of the Novo Nordisk Foundation, Lars Rebien Sørenen, will join the Novo Nordisk board, unitearly as an observer.
Novo last week reported that sales of the first quarter lower than the expected of its drug flagship and cut their sales growth prognosis throughout the year in the midst of greater competition of compound drug markets in the United States.
“The compounds took a part of our business,” Jørgensen told Charlotte Reed from CNBC.
However, the company never said that sales would improve in the second half of the year, since the availability of medicines composed of imitation is eliminated after the Food and Drug Administration (FDA) ended its decision of drug shortage.
Meanwhile, Novo has fought to shake the negative feeling after a series of disappointing results of the trials for its candidate for the next -generation obesity drug. Jørgensen said previously that he was “very optimistic” about the prospects of treatment.
“From the data we have, Cagrisema is the best product that has been tested or in the market, and we believe that we can obtain those data even better.”
